10323: NCI Moonshot Biobank (TMK)

Inclusion Criteria:
*  Is consistent with OR has been diagnosed with one of the following:
*  Colorectal cancer: Stage IV
*  Non-small cell or small cell lung cancer: stage III/IV
*  Prostate cancer: metastatic prostate cancer
*  Gastric cancer, not otherwise specified (NOS): stage IV
*  Esophageal cancer, NOS: stage IV
*  Adenocarcinoma of gastroesophageal junction: stage IV
*  High grade serous ovarian cancer: stage III/IV
*  Invasive breast carcinoma: stage III/IV
*  Melanoma: stage III/IV
*  Acute myeloid leukemia
*  Multiple myeloma
*  For the purposes of this study, re-staging is allowed
*  Patient should fit in one of the following four clinical scenarios (a-d)
*  Undergoing diagnostic workup for one of the diseases listed for which treatment will likely include a new regimen of standard of care therapy OR
*  Scheduled to begin treatment with a new regimen of standard of care therapy OR
*  Currently progressing on a regimen of standard of care therapy OR
*  Currently being treated with a regimen standard of care therapy, without evidence of progression
*  Requirements for fresh tissue biospecimen collections at enrollment:
*  For clinical scenarios a, b, and c above, freshly collected tumor tissue or bone marrow (BM) aspirate must be submitted at enrollment
*  For clinical scenarios a and b, the fresh tissue collection must be prior to starting therapy
*  For clinical scenario a, the biospecimen collection must be part of a standard of care medical procedure
*  For clinical scenarios b or c, the biospecimen collection may be part of a standard of care medical procedure OR
*  The biospecimen collection may be part of a study-specific procedure ("research only biopsy"), when the patient has a tumor amenable to image guided or direct vision biopsy and is willing and able to undergo a tumor biopsy for molecular profiling
*  Note: For research-only biopsies, the biopsy must not be associated with a significant risk of severe or major complications or death; the procedure cannot be a mediastinal, laparoscopic, open or endoscopic biopsy; nor can the procedure be a brain biopsy; nor can the patient be under the age of majority as determined by each U.S. state
*  Requirements for archival tissue:
*  For clinical scenarios a and b above, archival tissue as outlined below must be submitted IF AVAILABLE
*  For clinical scenarios c and d above, archival tissue as outlined below is REQUIRED
*  Pre-existing archival material (formalin-fixed, paraffin-embedded \[FFPE\] block, BM aspirate, or unstained slides) that:
*  Contains the cancer type for which the participant is enrolled, and
*  Was collected no more than 5 years prior to initiation of therapy, and
*  Contains at least a surface area of 5 mm\^2 and optimum surface area of 25 mm\^2 or 3-5 mL cryopreserved bone marrow aspirate to yield 200 million bone marrow mononuclear cells, and
*  No more than 1 line of standard of care systemic therapy was administered from the date of archival material collection to the date of initiation of therapy
*  Requirements for blood collection: ALL scenarios require fresh blood collection at enrollment
*  Blood collection for clinical scenarios a, b, and c must take place within 1 week of fresh tumor specimen collection
*  Blood collection for clinical scenario d must take place within 4 weeks of enrollment
*  Age 13 or older
*  Any sex and any gender
*  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2
*  Ability to understand and willingness to sign an informed consent document. Consent may be provided by a Legally Authorized Representative (LAR) in accordance with 45 CFR 46.102(i)

Exclusion Criteria:
*  Treated with or has already begun treatment with a non-standard of care therapeutic agent (investigational) in an interventional clinical trial
*  Uncontrolled intercurrent illness that in the physician's assessment would pose undue risk for biopsy
*  Use of full dose coumarin-derivative anticoagulants such as warfarin are prohibited. Patients may be switched to low molecular weight (LMW) heparin at physician discretion
*  Low molecular weight (LMW) heparin is permitted for prophylactic or therapeutic use
*  Factor X inhibitors are permitted
*  Use of anti-platelet drugs are permitted
*  Stopping the anticoagulation treatment for biopsy, bone marrow aspirate, or resection should be per site standard operating procedure (SOP)
*  NCI PDMR

Exclusion Criteria: Patients with CRC that is not mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H)
*  NCI PDMR

Exclusion Criteria: Patients with complete response
*  NCI PDMR

Exclusion Criteria: Patients with invasive fungal infections
*  NCI PDMR

Exclusion Criteria: Patients with active and/or uncontrolled infections or who are still recovering from an infection
*  Actively febrile patients with uncertain etiology of febrile episode
*  All antibiotics for non-prophylactic treatment of infection should be completed at least 1 week (7 days) prior to collection
*  No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
*  NCI PDMR

Exclusion Criteria: Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e. quantifiable hepatitis B virus \[HBV\]-deoxyribonucleic acid \[DNA\] and/or positive hepatitis B surface antigen \[HbsAg\], quantifiable hepatitis C virus \[HCV\]-ribonucleic acid \[RNA\]) or known history of HBV/HCV without documented resolution